Insulet Corporation (PODD) has recently garnered significant investor interest with a series of meaningful announcements. The company has taken over
commercial support and distribution of its
Omnipod® System in Europe and successfully launched
Omnipod 5 in five European countries. It has led to increased
revenue growth, achieving a 26% year-over-year rise in Q3 2024. Insulet also won a massive
$452M trade secret case against EOFlow Co., defending its intellectual property successfully. The company's shares performed well, gaining 10% within a week, and even
reaching a new 52-week high. Released Q4 2024 earnings date indicates that the company is performing well financially. The commitment to expanding portfolio became evident with the
launch of Omnipod 5 with Abbott's CGM in the US and it being cleared for patients with Type 2 diabetes by FDA. The product is also compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S. Insulet has also seen significant investment activities from reputed firms like
Summit Trail Advisors LLC, Choreo LLC, and Sargent Investment Group LLC.
Insulet Corporation PODD News Analytics from Wed, 20 Mar 2024 07:00:00 GMT to Sat, 15 Feb 2025 20:18:54 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -4
